
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is a promising investment opportunity as the company is at a pivotal point in multiple clinical trials for potential therapies. With projected revenue from Jemperli and promising results from imsidolimab, the company has the potential for significant revenue growth in the near future. However, investors should also consider potential risks such as ongoing litigation and financial obligations.
Bears say
AnaptysBio is a clinical-stage biotechnology company with a narrow product portfolio focused on developing immune cell modulating antibodies for inflammatory and oncology indications. While the company has potential near-term catalysts such as the potential approval of Jemperli in locally advanced rectal cancer, the opportunity is smaller than their existing endometrial cancer franchise. The company also faces ongoing litigation and regulatory risks that could impede its future success.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares